Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTA/NOTA-FAPI-04 PET/CT in Patients With Various Types of Cancer
NCT04499365Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2020
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-DOTA/NOTA-FAPI-04 in cancer, sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Standardized uptake value at 30 days. Started Aug 2020; status: recruiting.
02
Drugs
68Ga-DOTA/NOTA-FAPI-04
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04499365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499365.